Homepage
Author:
Revolution Medicines, Inc.
Posted Date:
April 15, 2026
Revolution Medicines, Inc. Prices $2.0 Billion in Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes
Revolution Medicines, Inc.
April 15, 2026
Revolution Medicines, Inc. Announces Proposed Offerings of Common Stock and Convertible Senior Notes
Revolution Medicines, Inc.
April 13, 2026
Daraxonrasib Demonstrates Unprecedented Overall Survival Benefit in Pivotal Phase 3 RASolute 302 Clinical Trial in Patients with Metastatic Pancreatic Cancer
Revolution Medicines, Inc.
April 13, 2026
Revolution Medicines Begins Treating Patients in Phase 3 RASolute 303 Trial Evaluating Daraxonrasib as First Line Treatment for Patients with Metastatic Pancreatic Cancer
Revolution Medicines, Inc.
April 2, 2026
Revolution Medicines to Showcase Progress Across RAS(ON) Targeted Oncology Pipeline with Multiple Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting
Revolution Medicines, Inc.
March 17, 2026
Revolution Medicines Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress
Revolution Medicines, Inc.
February 25, 2026
Revolution Medicines to Participate in TD Cowen 46th Annual Health Care Conference
Revolution Medicines, Inc.
February 24, 2026
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2025 After Market Close on February 25, 2026
Revolution Medicines, Inc.
February 18, 2026
Revolution Medicines to Participate in Guggenheim Securities Emerging Outlook: Biotech Summit 2026
Revolution Medicines, Inc.
February 7, 2026
Revolution Medicines Doses First Patient in Clinical Trial Evaluating RMC-5127, a RAS(ON) G12V-Selective Inhibitor
Revolution Medicines, Inc.
January 29, 2026
Prev
1
2
